Medical Food Improves Nutritional, Cognitive Status of Patients With Mild Alzheimer's Disease: Presented at ADI
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Medical Food Improves Nutritional, Cognitive Status of Patients With Mild Alzheimer's Disease: Presented at ADI

By Jenny Powers

THESSALONIKI, Greece -- March 13, 2010 -- Data from a study presented here at the 25th Conference of Alzheimer’s Disease International (ADI) on March 11 demonstrated that a medical food containing a combination of nutrients significantly lowered homocysteine levels and improved cognitive function, especially delayed memory, in patients with mild Alzheimer’s disease (AD).

Frank H. Pistoor, PhD, Nutricia Advanced Medical Nutrition, Schiphol, the Netherlands, delivered the results of the randomised, double-blind, controlled trial.

The medical food was developed following 10 years of research on the impact of nutrients on cognitive function in patients with AD. It contains nutrients such as omega 3 fatty acid, choline, and antioxidants that are substrates for the synthesis of nerve synapses.

The study involved 212 drug-naïve patients with mild AD. Half of the patients received the medical food and the other received placebo over the course of 12 weeks.

Cognitive function was evaluated using a delayed verbal memory task (Wechsler Memory Scale-revised) and the 13-item modified Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog).

Significant benefit in cognitive function from baseline was observed in patients receiving the medical food, as demonstrated by an improvement on the delayed verbal memory task, compared with patients receiving placebo (P = .026). No improvement in scores was seen in the control group.

A significant improvement was also seen in the Mini-Mental State Examination score of 40% of the treated patients (P = .011).

The treated patients also had a significant decrease in homocysteine levels, compared with patients in the placebo group (P = .001)

Although unadjusted analyses showed no significant effect on ADAS-cog, baseline ADAS-cog score was a predictor for the intervention effect (ie, patients with a higher baseline score showed a greater effect of the medical food).

Two 24-week studies, which began in 2009, are expected to confirm these results. Results of both clinical studies are to be expected soon.

Funding for this study was provided by Nutricia Advanced Medical Nutrition.

[Presentation title: Efficacy of a Medical Food (Souvenaid) in Mild Alzheimer’s Disease: A Randomized Controlled Trial]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities